No further treatment. Reported efficacy for RTOG 9402 is based on the 2012 update; while the trial did not meet its primary endpoint, a survival benefit was noted in the population with 1p/19q co-deleted tumors. van den Bent et al. 2013 noted that 1p/19q co-deleted tumors received the more benefit from adjuvant PCV as compared to tumors without 1p/19q co-deletion.

Note: the abstract of Prados et al. 2004 does not have dosing details. Reported efficacy for RTOG 9402 is based on the 2012 update; while the trial did not meet its primary endpoint, a survival benefit was noted in the population with 1p/19q co-deleted tumors.

Chemotherapy

Supportive medications

Corticosteroid use was left up to physician discretion. It was recommended to not discontinue steroids until at least 6 weeks after radiation therapy. If it was to be discontinued, it should be tapered down gradually over several weeks, or could be titrated down to the lowest tolerated dose.

Subsequent treatment

References

MRC BR02: Bleehen NM, Stenning SP; The Medical Research Council Brain Tumour Working Party. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer. 1991 Oct;64(4):769-74. link to PMC articlecontains protocolPubMed